Riding on rosy estimates of Zolgensma sales, RegenxBio sells part of its royalty for $200M
RegenxBio’s journey as a drug developer may have been less than rosy, but there’s been little doubt about the value of the gene therapy technology …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
